Use of human material for evaluation of novel DNA pathway inhibitors
Research type
Research Study
Full title
Analysis of healthy and diseased human cells and tissues for evaluation of novel DNA repair pathway inhibitors.
IRAS ID
252924
Contact name
Graeme Smith
Contact email
Sponsor organisation
Artios Pharma Ltd
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Targeting of key pathways controlling DNA integrity in cancer can kill malignant cells either as a single agent or through sensitization to other DNA-damaging therapies.
Artios Pharma are developing small molecule inhibitors targeting such pivotal enzymes in the DNA damage repair process. As demonstrated by the success of PARP inhibitors in the clinic, these inhibitors hold a potential to be used as single agents in specific genetic backgrounds or in combination with other DNA-damage-inducing cancer therapies.
In addition to biochemical and in vitro studies utilising cancer cells, use of human primary cell lines and tissues will significantly boost our knowledge on the DNA damage repair targets studied, as well as their potential pharmacodynamic biomarkers and patient population most likely to respond to novel treatments.
Artios Pharma plan to use primary human blood cells and other tissues to develop target engagement, activity and diagnostic assays for our targets as well as to test for expression level of relevant targets and biochemical pathways affected by our novel inhibitors. Healthy and diseased human tissues will be predominantly used to test for the differential expression level of our targets, potential pharmacodynamic and prognostic biomarkers, thus facilitating precise patient selection for the therapies being developed at Artios Pharma.REC name
North of Scotland Research Ethics Committee 1
REC reference
18/NS/0111
Date of REC Opinion
25 Sep 2018
REC opinion
Favourable Opinion